Article Text

Download PDFPDF
Germline Mutations of BRCA1 and BRCA2 in Korean Ovarian Cancer Patients: Finding Founder Mutations
  1. Min Chul Choi, MD*,
  2. Jin-Hyung Heo, MD,
  3. Ja-Hyun Jang, MD, PhD,
  4. Sang Geun Jung, MD, PhD*,
  5. Hyun Park, MD, PhD*,
  6. Won Duk Joo, MD, PhD*,
  7. Chan Lee, MD, PhD*,
  8. Je Ho Lee, MD, PhD*,
  9. Jun Mo Lee, MD, PhD*,
  10. Yoon Young Hwang, MD, PhD* and
  11. Seung Jo Kim, MD, PhD*
  1. *Comprehensive Gynecologic Cancer Center, Departments of Obstetrics and Gynecology and
  2. Pathology, CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Republic of Korea; and
  3. GreenCross Laboratories, Yongin City, Republic of Korea.
  1. Address correspondence and reprint requests to Jun Mo Lee, MD, PhD, CHA Bundang Medical Center, Yatap-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-712, Republic of Korea. E-mail: leejm@catholic.ac.kr.

Abstract

Objectives To investigate and analyze the BRCA mutations in Korean ovarian cancer patients with or without family history and to find founder mutations in this group.

Methods/Materials One hundred two patients who underwent a staging operation for pathologically proven epithelial cancer between January 2013 and December 2014 were enrolled. Thirty-two patients declined to analyze BRCA1/2 gene alterations after genetic counseling and pedigree analysis. Lymphocyte specimens from peripheral blood were assessed for BRCA1/2 by direct sequencing.

Results BRCA genetic test results of 70 patients were available. Eighteen BRCA1/2 mutations and 17 unclassified variations (UVs) were found. Five of the BRCA1/2 mutations and 4 of the UVs were not reported in the Breast Cancer Information Core database. One BRCA2 UV (8665_8667delGGA) was strongly suspicious to be a deleterious mutation. BRCA1/2 mutations were identified in 11 (61.1%) of 18 patients with a family history and in 7 (13.5%) of 52 patients without a family history.

Candidates for founder mutations in Korean ovarian cancer patients were assessed among 39 BRCA1/2 mutations from the present study and from literature reviews. The analysis showed that 1041_1043delAGCinsT (n = 4; 10.2%) and 3746insA (n = 4; 10.2%) were possible BRCA1 founder mutations. Only one of the BRCA2 mutations (5804_5807delTTAA) was repeated twice (n = 2; 5.1%).

Conclusions The prevalence of BRCA1/2 mutations in Korean ovarian cancer patients irrespective of the family history was significantly higher than previously reported. Possible founder mutations in Korean ovarian cancer patients were identified.

  • BRCA mutation
  • Korean ovarian cancer
  • Founder mutation

Statistics from Altmetric.com

Supplementary materials

Related Data

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.